

October 31, 2023



# Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023

RADNOR, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2023, after the financial markets close on Tuesday, November 7, 2023.

***Tuesday, November 7<sup>th</sup> @ 4:30 p.m. ET***

Domestic: 1-888-886-7786

International: 1-416-764-8658

Conference ID: 27015887

Webcast: [Link](#)

If you would like a call back, please click this [link](#), which will be made active 15 minutes prior to the scheduled start time. A live webcast of the conference call may be found [here](#). A replay of the call will be available on the “[News & Events](#)” page in the Investor Relations section of the Mineralys Therapeutics website.

## **About Mineralys Therapeutics**

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit <https://mineralystx.com>. Follow Mineralys on [LinkedIn](#) and [Twitter](#).

## **Contact:**

### **Investor Relations**

[investorrelations@mineralystx.com](mailto:investorrelations@mineralystx.com)

### **Media Relations**

Tom Weible

Elixir Health Public Relations

Phone: (1) 515-707-9678  
Email: [tweible@elixirhealthpr.com](mailto:tweible@elixirhealthpr.com)



Source: Mineralys Therapeutics, Inc.